Pragmatic Considerations in Switching to Semaglutide for Obesity Management: Real- World Perspectives
Incretin-based therapies have transformed the management of obesity and related cardiometabolic diseases. With the increasingavailability of agents such as semaglutide and tirzepatide, switches between therapies are occurring in clinical practice despitethe absence of formal randomized evidence guiding such transitions. This review outlines pragmatic, experience-basedconsiderations for switching from tirzepatide to semaglutide including clinical rationale, dose conversion approaches, titrationstrategies, and cost-sensitive implementation. These practical insights aim to support clinicians in optimizing individualized,safe, and cost-effective obesity management.
Authors
- Dicky L. Tahapary (ORCID: https://orcid.org/0000-0002-4048-5159)
- Siew Pheng Chan (ORCID: https://orcid.org/0000-0002-7031-7594)
- Jeyakantha Ratnasingam (ORCID: https://orcid.org/0000-0002-4993-6470)
- Vivien Lim
- Dr SANJAY KALRA
- Dr KETUT SUASTIKA
- Dr NITIN KAPOOR
- Dr SHAHJADA SELIM
- Dr CHAICHARN DEEROCHANAWONG
- Dr JEREMY JONES ROBLES
Institutions
- Udayana University (ID)
- University Malaya Medical Centre (MY)
- Christian Medical College, Vellore (IN)
- Bangladesh University (BD)
- Gleneagles Hospital (SG)
- University of Indonesia (ID)
- University of Malaya (MY)
- Universitas Mahasaraswati Denpasar (ID)
- Subang Jaya Medical Centre (MY)
- Bharti Hospital (IN)
- Rumah Sakit Umum Pusat Nasional Dr. Cipto Mangunkusumo (ID)
- Chang Hua Hospital (TW)
- Rangsit University (TH)
Publication Details
- Published
- 2026-05-01
- DOI
- https://doi.org/10.59793/bzsxq840
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00